Pertuzumab

Pertuzumab
The structure of HER2 and pertuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetHER2
Clinical data
Trade namesPerjeta
Other names2C4
License data
Pregnancy
category
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
 ☒NcheckY (what is this?)  (verify)

Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.[4]

Side effects in more than half the people taking it include diarrhea, hair loss, and loss of neutrophils; more than 10% experience loss of red blood cells, hypersensitivity or allergic reaction, infusion reactions, decreased appetite, insomnia, distortions in the sense of taste, inflammation of the mouth or lips, constipation, rashes, nail disease, and muscle pain.[3] Women who are pregnant or planning on getting pregnant should not take it, it was not studied in people with certain heart conditions and should be used in caution in such people, and it should not be used with an anthracycline.[3] It is unknown if pertuzumab interacts with doxorubicin.[3]

It is the first-in-class of a kind of drug called a "HER dimerization inhibitor" — it inhibits the dimerization of HER2 with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation.[6]

It was discovered and developed by Genentech and was first approved in 2012.[7][8]

  1. ^ a b "AUSTRALIAN PRODUCT INFORMATION – Perjeta® (pertuzumab)". Retrieved 12 July 2024.
  2. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  3. ^ a b c d Cite error: The named reference Perjeta SmPC was invoked but never defined (see the help page).
  4. ^ a b Cite error: The named reference Perjeta FDA label was invoked but never defined (see the help page).
  5. ^ "Perjeta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 16 September 2021. Retrieved 3 January 2022.
  6. ^ Cite error: The named reference Harbeck2013rev was invoked but never defined (see the help page).
  7. ^ "Drug Approval Package: Perjeta (pertuzumab) Injection NDA #125409". U.S. Food and Drug Administration (FDA). 3 August 2012. Archived from the original on 3 January 2022. Retrieved 3 January 2022.
  8. ^ Cite error: The named reference FDA2012 was invoked but never defined (see the help page).